Evidence map›Paper›PMID 37873448›Full record

ArticlebioRxiv : the preprint server for biology2024

Delivery of A Jagged1-PEG-MAL hydrogel with Pediatric Human Bone Cells Regenerates Critically-Sized Craniofacial Bone Defects.

Archana Kamalakar, Brendan Tobin, Sundus Kaimari, M Hope Robinson, Afra I Toma, Timothy Cha, Samir Chihab, Irica Moriarity, Surabhi Gautam, Pallavi Bhattaram and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Archana KamalakarDepartment of Pediatric Otolaryngology, Emory University, Atlanta, GA, USA.
Brendan TobinParker H. Petit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA, USA.
Sundus KaimariDepartment of Pediatric Otolaryngology, Emory University, Atlanta, GA, USA.
M Hope RobinsonDepartment of Pediatric Otolaryngology, Emory University, Atlanta, GA, USA.
Afra I TomaDepartment of Pediatric Otolaryngology, Emory University, Atlanta, GA, USA.
Timothy ChaDepartment of Pediatric Otolaryngology, Emory University, Atlanta, GA, USA.
Samir ChihabDepartment of Orthopedics, Emory University, Atlanta, GA, USA.
Irica MoriarityNeuroscience Program in College of Sciences, Georgia Institute of Technology, Atlanta, GA, USA.
Surabhi GautamDepartment of Orthopedics, Emory University, Atlanta, GA, USA.
Pallavi BhattaramDepartment of Orthopedics, Emory University, Atlanta, GA, USA.
Shelly AbramowiczDepartment of Pediatric Otolaryngology, Emory University, Atlanta, GA, USA.
Hicham DrissiDepartment of Cell biology, Emory University, Atlanta, GA, USA.
Andrés J GarcíaParker H. Petit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA, USA.
Levi B WoodWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Steven L GoudyDepartment of Pediatric Otolaryngology, Emory University, Atlanta, GA, USA.
Emory University · USGeorgia Institute of Technology · US

Funding

Hydrogels for hMSC delivery & engraftmentR01AR062368 · NIAMS · GEORGIA INSTITUTE OF TECHNOLOGY · PI GARCIA, ANDRES J · 2012 to 2022
$3.5M
Osseo-reparative, integrin-specific materialsR01AR062920 · NIAMS · GEORGIA INSTITUTE OF TECHNOLOGY · PI GARCIA, ANDRES J · 2012 to 2021
$3.2M
Jagged1-based craniofacial bone regenerationR01DE031271 · NIDCR · EMORY UNIVERSITY · PI Moulay Hicham DRISSI, Steven L Goudy · 2022 to 2026
$2.2M
Targeted Regenerative Therapy to Treating Pediatric Maxillary Bone DeficiencyR56DE026762 · NIDCR · EMORY UNIVERSITY · PI GOUDY, STEVEN L · 2018 to 2018
$390k
NIAMS NIH HHS R01 AR062368NIAMS NIH HHS R01 AR062920NIDCR NIH HHS R01 DE031271NIDCR NIH HHS R56 DE026762
6 · The paper itself

Abstract

Treatments for congenital and acquired craniofacial (CF) bone abnormalities are limited and expensive. Current reconstructive methods include surgical correction of injuries, short-term bone stabilization, and long-term use of bone grafting solutions, including implantation of (i) allografts which are prone to implant failure or infection, (ii) autografts which are limited in supply. Current bone regenerative approaches have consistently relied on BMP2 application with or without addition of stem cells. BMP2 treatment can lead to severe bony overgrowth or uncontrolled inflammation, which can accelerate further bone loss. Bone marrow-derived mesenchymal stem cell-based treatments, which do not have the side effects of BMP2, are not currently FDA approved, and are time and resource intensive. There is a critical need for novel bone regenerative therapies to treat CF bone loss that have minimal side effects, are easily available, and are affordable. In this study we investigated novel bone regenerative therapies downstream of JAGGED1 (JAG1). We previously demonstrated that JAG1 induces murine cranial neural crest (CNC) cells towards osteoblast commitment via a NOTCH non-canonical pathway involving JAK2-STAT5 (1) and that JAG1 delivery with CNC cells elicits bone regeneration in vivo. In this study, we hypothesize that delivery of JAG1 and induction of its downstream NOTCH non-canonical signaling in

Indexed as

Bone RegenerationCraniofacial Bone DefectsHuman Bone-derived Osteoblast-like CellsJAGGED1Non-canonical JAG1-NOTCH pathwaysPEG-4MAL Hydrogel-based deliveryRNA Sequencing

Identifiers

PMID37873448
PMCPMC10592619
OpenAlexW4387488586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.